367 related articles for article (PubMed ID: 29546453)
1. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
5. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
Raje N; Woo SB; Hande K; Yap JT; Richardson PG; Vallet S; Treister N; Hideshima T; Sheehy N; Chhetri S; Connell B; Xie W; Tai YT; Szot-Barnes A; Tian M; Schlossman RL; Weller E; Munshi NC; Van Den Abbeele AD; Anderson KC
Clin Cancer Res; 2008 Apr; 14(8):2387-95. PubMed ID: 18413829
[TBL] [Abstract][Full Text] [Related]
6. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
Bejhed RS; Kharazmi M; Hallberg P
Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
[TBL] [Abstract][Full Text] [Related]
7. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
[TBL] [Abstract][Full Text] [Related]
8. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
9. Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease.
Kim JW; Tatad JCI; Landayan MEA; Kim SJ; Kim MR
Bone; 2015 Dec; 81():442-448. PubMed ID: 26297440
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw.
Fung PL; Nicoletti P; Shen Y; Porter S; Fedele S
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):537-46. PubMed ID: 26299425
[TBL] [Abstract][Full Text] [Related]
13. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Wehrhan F; Hyckel P; Amann K; Ries J; Stockmann P; Schlegel K; Neukam F; Nkenke E
Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
[TBL] [Abstract][Full Text] [Related]
14. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
[TBL] [Abstract][Full Text] [Related]
15. Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer.
Ripamonti CI; Lucchesi M; Giusti R
Curr Opin Support Palliat Care; 2016 Sep; 10(3):273-80. PubMed ID: 27380219
[TBL] [Abstract][Full Text] [Related]
16. Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gas insufflation. A case report.
Ripamonti CI; Maniezzo M; Pessi MA; Boldini S
Tumori; 2012; 98(3):72e-75e. PubMed ID: 22825522
[TBL] [Abstract][Full Text] [Related]
17. Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw.
Allegra A; Mania M; D'Ascola A; Oteri G; Siniscalchi EN; Avenoso A; Innao V; Scuruchi M; Allegra AG; Musolino C; Campo S
Biomed Res Int; 2020; 2020():9879876. PubMed ID: 32714991
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
19. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F
Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267
[TBL] [Abstract][Full Text] [Related]
20. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
